Lupus & antiphospholipid syndrome
Relevance of inflammatory and complement activation biomarkers profiling in antiphospholipid syndrome patients outside acute thrombosis
Authors' conclusion
Our findings suggested that APS patients outside acute thrombosis might be divided into two clusters: "inflammatory" and "complement". Elevated IL-6 was associated with cardiovascular risk factors and metabolic parameters, whereas Bb fragments, a marker of alternative pathway complement activation, was strongly associated with aPL profile at highest risk of severe disease.
Study context
- Population
- Unselected antiphospholipid syndrome (APS) patients outside acute thrombosis, January 2020 to April 2021 (median time from last APS manifestation 60 (23;132) months)
- Participants
- 98 vs 25
- Exposure
- APS patients outside acute thrombosis vs healthy blood donors
- APSn = 98
- Controlsn = 25reference
- Outcome
- Association of serum inflammatory and plasma complement biomarkers with specific characteristics of APS
Methodological detailscluster analysis
- Cluster analysis
Main finding
As reported in the abstract
APS patients with elevated levels of at least one complement biomarker
85%
APS patients with elevated Bb (associated with aPL positivities)
34%
Patients with history of catastrophic APS with elevated complement biomarkers
7 of 8
Observational data: associations, not effects.
Further findings
Elevated Bb, triple aPL positivity vs not
- Elevated Bb with vs without triple aPL positivity (p<0.001)
- 50% vs. 18%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →